Vickie Sinibaldi

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Suramin 49%
3. Castration 43%
4. Prostate-Specific Antigen 39%
5. Androgens 37%
6. Docetaxel 27%
7. Sunitinib 26%
8. Renal Cell Carcinoma 23%
9. Hormones 21%
10. Progression-Free Survival 21%
11. hexamethylene bisacetamide 20%
12. Survival 19%
13. Therapeutics 18%
14. Carboplatin 18%
15. Pharmacokinetics 16%
16. abiraterone 13%
17. MDV 3100 12%
18. Estramustine 12%
19. Radiotherapy 11%
20. Androgen Receptors 11%
21. Carcinoma 10%
22. Ketoconazole 10%
23. Izonsteride 9%
24. Disease Progression 9%
25. Appointments and Schedules 9%
26. Prostate 9%
27. Neoplasms 8%
28. Head and Neck Neoplasms 8%
29. Menogaril 7%
30. lestaurtinib 7%
31. sulindac sulfone 7%
32. marimastat 7%
33. Phosphates 7%
34. Phenylbutyrates 7%
35. Atrasentan 6%
36. Squamous Cell Carcinoma of Head and Neck 6%
37. Androgen Antagonists 6%
38. Pharmaceutical Preparations 6%
39. 5-alpha Reductase Inhibitors 6%
40. Abiraterone Acetate 6%
41. Quality of Life 6%
42. 4-phenylbutyric acid 6%
43. Neutrophils 6%
44. Neck 6%
45. Safety 6%
46. Guidelines 6%
47. bicalutamide 6%
48. Head 5%
49. Lymphocytes 5%
50. Thioguanine 5%